Cardiol Therapeutics Inc. (TSE:CRDL) has released an update.
Cardiol Therapeutics Inc. has presented its Phase II ARCHER trial data at the World Congress on Acute Heart Failure, highlighting the study’s focus on evaluating CardiolRx™ in patients with acute myocarditis. The trial has surpassed 85% of its enrollment target, with topline results expected in June 2024. Additionally, the company is progressing with its MAvERIC-Pilot Phase II study on recurrent pericarditis, aiming to enhance treatment options for heart disease.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
